Teva is lined up to copy 7 of the blockbuster drugs on this tracker, which earned $38.2B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Teva's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Stelara Selarsdi |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved biosimilar | $6.1B |
| Prolia Ponlimsi |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $4.4B |
| Farxiga | AstraZeneca | Generic | 2026 | Approved Apr 2026 | $8.4B |
| Pomalyst | Bristol Myers Squibb | Generic | 2026 | Approved May 2022 | $2.7B |
| Cabometyx | Exelixis | Generic | 2031 | Settled; license from 1 Jan 2031 | $2.1B |
| Entyvio AVT16 |
Takeda | Biosimilar | 2032 | Under FDA review; decision expected Q1 2027 | ≈$6.0B |
| Ocrevus PB018 |
Roche | Biosimilar | 2029 | Phase 1 planned, Oct 2026 | ≈$8.4B |
Company facts: SEC company tickers. Each drug page lists sources for these entries. Brand sales show the size of the market, not Teva's share of it.